2025 Market Reports Update: Market Size Forecasts to 2034, Key Trends, Leading Players, and Top Regions – Get Ahead of the Competition Today!

How Are Key Drivers in the Industry Acting as Catalysts for the Growth of theVasomotor Menopausal Symptoms (VMS) Treatment Market?

The anticipated rise in the number of menopausal women is projected to boost the expansion of the vasomotor menopausal symptoms treatment market. Menopause is a natural, biological phase reflecting the end of childbearing years for a woman. It usually affects women between 45 to 55 years old, with the median age being 51. The growth in the number of women experiencing menopause, who require alleviation for symptoms such as hot flashes and vaginal dryness on a global scale, is one of the crucial factors propelling the growth of vasomotor menopausal symptoms (VMS) treatment. For example, as per the Cuyuna Regional Medical Center, a US healthcare establishment, they expect that by 2025, a population of 1.1 billion women will have entered menopause because of increased lifespan. Additionally, they estimate that the population of menopausal women will grow by 1.6% each year until 2060. Consequently, the expansion in the population of menopausal women is fueling the vasomotor menopausal symptoms treatment market. Furthermore, the initiatives taken by governments for health issues surrounding menopause are projected to stimulate the growth of the vasomotor menopausal symptoms treatment market. These government initiatives involve fund provisions for revolutionary menopausal transition studies, prevention of diseases, and pharmacological, clinical, and epidemiological research. These endeavors are incorporated into larger women’s healthcare initiatives that cover diverse issues. For instance, as stated by the New South Wales government of Australia in January 2023, they have allocated $40.3 million over four years (2022-2023 to 2025-2026) to establish up to 16 new programs dedicated to women struggling with severe menopausal symptoms. Hence, such government initiatives aimed at catering to women’s health in menopause are propelling the vasomotor menopausal symptoms treatment market.

Get Your Free Sample Report Now – Explore Exclusive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=13051&type=smp

#What is the Anticipated CAGR of theVasomotor Menopausal Symptoms (VMS) Treatment Market, and What Factors Will Drive It?

In the past years, the market for vasomotor menopausal symptoms (VMS) treatment has seen substantial growth. The market value is expected to escalate from $17.86 billion in 2024 to $19.19 billion in 2025, with a compound annual growth rate (CAGR) of 7.5%. Factors like hormone replacement therapy (hrt), awareness about menopause, advancements in the pharmaceutical industry, and consumer demand are some of the key attributors to the growth seen in the historic period.

The market for treating vasomotor menopausal symptoms (VMS) is projected to experience robust expansion in the coming years. The market size is forecasted to reach $24.81 billion by 2029, with a compound annual growth rate (CAGR) of 6.6%. This anticipated market growth during the forecast period can be linked to precise medicine, breakthroughs in non-hormonal treatments, nutritional and dietary measures, as well as the integration of telemedicine and digital health. The period is also expected to be characterized by trends such as natural and alternative treatments, herbal and botanical remedies, menopause support groups, and cognitive behavioral therapy (CBT).

You can Directly Purchase the Report Here:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=13051

What Are the Current Market Growth and Trends in theVasomotor Menopausal Symptoms (VMS) Treatment Market That Industry Players Should Watch?

Significant businesses in the vasomotor menopausal symptoms treatment sector are progressing with product development efforts like Veozah and seeking approvals to present fresh therapeutic alternatives and cater to the unmet medical requirements of patients. The sanction of novel medications for menopause enhances effectiveness and safety over existing treatments. For instance, in May 2023, approval was granted for Veozah (fezolinetant) 45 mg daily by the US-based Food and Drug Administration (FDA) to Astellas Pharma Inc., a pharmaceutical organization based in Japan. This drug is for the treatment of various degrees of menopausal vasomotor symptoms (VMS). Veozah is the inaugural nonhormonal neurokinin 3 (NK3) receptor antagonist permitted for use in dealing with VMS linked to menopause. It functions as a hormone-free solution that inhibits a pathway in the brain that controls these symptoms. It offers an alternate treatment choice for women enduring these symptoms, especially those who cannot or choose not to undergo hormone therapy. The validation of Veozah underscores its potential as a freshly researched drug for handling menopausal symptoms.

What Are the Major Market Players Making an Impact on theVasomotor Menopausal Symptoms (VMS) Treatment Market Growth?

Major companies operating in the vasomotor menopausal symptoms (vms) treatment market are Pfizer Inc., Abbvie Inc., Novartis AG, Ausio Pharmaceuticals LLC, Teva Pharmaceutical Industries Ltd., Mylan N.V., Sun Pharmaceutical Industries Ltd., Aurobindo Pharma Limited, Kyowa Kirin Co. Ltd., Dr. Reddy’s Laboratories Ltd., Alembic Pharmaceuticals Limited Inc., Apotex Inc., Hikma Pharmaceutical PLC, Endo Pharmaceuticals PLC, Amneal Pharmaceuticals LLC, Mundipharma International Ltd., Lupin Limited, Glenmark Pharmaceuticals Ltd., Hisamitsu Pharmaceutical Co. Inc., Zhejiang Huahai Pharmaceutical Co. Ltd., Emcure Pharmaceuticals Limited, Wockhardt Pvt. Ltd., QuatRx Pharmaceuticals Company, Bionovo Inc., Mithra Pharmaceuticals SA, EndoCeutics Inc., Zydus Group, Edgemont Pharmaceuticals LLC, MenoGeniX Inc., Agile Therapeutics Inc.

Order Your Report Now For A Swift Delivery:

https://www.thebusinessresearchcompany.com/report/vasomotor-menopausal-symptoms-vms-treatment-global-market-report

How Are the Key Segments of the Vasomotor Menopausal Symptoms (VMS) Treatment Market Driving Opportunities and Innovations?

The vasomotor menopausal symptoms (VMS) treatment market covered in this report is segmented –

1) By Drug Class: Antidepressants, Fluoxetine, Paroxetine, Sertraline, Hormone Therapy, Anticonvulsant, Phenytoin, Phenobarbital, Other Drug Classes

2) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Other Distribution Channels

3) By End-User: Hospitals, Specialty Clinics, Homecare, Other End-Users

Subsegments:

1) By Antidepressants: SSRIs (Selective Serotonin Reuptake Inhibitors), SNRIs (Serotonin-Norepinephrine Reuptake Inhibitors), TCAs (Tricyclic Antidepressants), MAOIs (Monoamine Oxidase Inhibitors), Atypical Antidepressants

2) By Fluoxetine: Depression, Obsessive-Compulsive Disorder (OCD), Panic Disorder, Generalized Anxiety Disorder (GAD), Post-Traumatic Stress Disorder (PTSD), Social Anxiety Disorder, Premenstrual Dysphoric Disorder (PMDD)

3) By Paroxetine: Depression, Obsessive-Compulsive Disorder (OCD), Panic Disorder, Generalized Anxiety Disorder (GAD), Post-Traumatic Stress Disorder (PTSD), Social Anxiety Disorder, Premenstrual Dysphoric Disorder (PMDD)

4) Sertraline: Depression, Obsessive-Compulsive Disorder (OCD), Panic Disorder, Post-Traumatic Stress Disorder (PTSD), Social Anxiety Disorder, Premenstrual Dysphoric Disorder (PMDD)

5) Hormone Therapy: Estrogen Replacement Therapy (ERT), Progestin Therapy, Combined Hormonal Therapy (CHT), Testosterone Replacement Therapy (TRT)

6) Anticonvulsant: Hydantoins, Barbiturates, Benzodiazepines, Valproates, Succinimides, Carboxylic Acid Derivatives

7) Phenytoin: Hydantoins

8) Phenobarbital: Barbiturates

9) Other Drug Classes: Antibiotics, Analgesics, Antidiabetics, Antihypertensives, Anticoagulants, Immunosuppressants, Antipsychotics, Antihistamines

Gain Exclusive Market Insights—Customize Your Research Report Today for Fast Delivery!

https://www.thebusinessresearchcompany.com/customise?id=13051&type=smp

What Regions Are At the Forefront of #How Are Key Drivers in the Industry Acting as Catalysts for the Growth of theVasomotor Menopausal Symptoms (VMS) Treatment Market?# Market Expansion?

North America was the largest region in the vasomotor menopausal symptoms (VMS) treatment market in 2024. The regions covered in vasomotor menopausal symptoms (VMS) treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Browse Through More Reports Similar to the Global Vasomotor Menopausal Symptoms (VMS) Treatment Market 2025, By The Business Research Company:

Insulin Drugs Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/insulin-drugs-global-market-report

Polycystic Ovarian Syndrome Treatment Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/polycystic-ovarian-syndrome-treatment-global-market-report

Smart Insulin Pens Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/smart-insulin-pens-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at [email protected]

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: